Comparative Pharmacology
Head-to-head clinical analysis: BENDECTIN versus TIGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENDECTIN versus TIGAN.
BENDECTIN vs TIGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of doxylamine (antihistamine) and pyridoxine (vitamin B6). Doxylamine blocks histamine H1 receptors, reducing nausea and vomiting. Pyridoxine acts as a cofactor in neurotransmitter synthesis, modulating nausea pathways.
TIGAN (trimethobenzamide) acts on the chemoreceptor trigger zone (CTZ) to inhibit emetic stimuli, primarily through antagonism of dopamine D2 receptors, though its exact mechanism is not fully elucidated.
10 mg doxylamine succinate + 10 mg pyridoxine hydrochloride orally once daily at bedtime, increased to twice daily (one tablet in morning and one at bedtime) and then three times daily (one tablet in morning, one in midafternoon, and one at bedtime) as needed, max 4 tablets per day.
Adults: 200 mg IM or 100 mg PO or 200 mg PR every 6–8 hours as needed.
None Documented
None Documented
Doxylamine: 10-12 hours (range 6-15h) in healthy adults; prolonged in hepatic impairment or elderly. Pyridoxine: 15-20 days (as pyridoxal phosphate in tissues); elimination half-life of pyridoxine per se is 2-3 hours.
12-15 hours; may be prolonged in hepatic impairment.
Renal: mostly as metabolites. Doxylamine: ~60% as unchanged drug and metabolites; pyridoxine: ~70-80% as metabolites (primarily 4-pyridoxic acid). Fecal: minimal (<10%) for both components.
Renal (30-50% as unchanged drug and metabolites), biliary/fecal (minor).
Category C
Category C
Antiemetic
Antiemetic